News

MedAlliance Receives FDA Breakthrough Device Designation Status for Sirolimus Drug-Eluting Balloon to Treat Below-the-Knee Disease

MedAlliance, the first drug-eluting balloon company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for the treatment of coronary ISR, has been awarded similar status for SELUTION SLR™, its sustained limus release drug-eluting balloon (DEB) catheter, for the treatment of Below-the-Knee Disease.

read more

MedAlliance Raises $37 Million to Launch Sirolimus Drug-Coated Balloon

M.A. MedAlliance SA, a company developing and commercializing the first sirolimus micro-reservoir drug-coated balloon (SELUTION™ DCB) to treat patients suffering from peripheral artery disease (PAD), coronary artery disease (CAD), arteriovenous fistulas (AVF) and grafts (AVG) for end-stage renal disease, has raised $37 million.

read more

SELUTION™ First-in-Man Study Achieves Primary Endpoint

Primary endpoint data from the First-in-Man (FIM) study of SELUTION™, Med Alliance’s novel sirolimus-coated balloon, was presented today at the Leipzig Interventional Course (LINC) by Principal Investigator Professor Thomas Zeller, Universitaets-Herzzentrum, Bad Krozingen, Germany.

read more

Med Alliance Announces Strategic Agreement with Kaneka Corporation

Swiss-based medical technology company Med Alliance has announced a strategic agreement with Kaneka Corporation, Japan’s leading provider of PTCA balloons. The agreement involves technical collaboration, product licensing, manufacturing and distribution for the Med Alliance sirolimus Drug-Coated Balloon (DCB) in Japan for the treatment of coronary arteries.

read more